Antagonism of endothelin actions
US5688499A · kind A · utility
12Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 1996 |
| Grant date | Nov 18, 1997 |
| Priority date | — |
| Expiry date | Mar 13, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The mechanism of hypertension following acute NO synthase blockade is via endothelin mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a `normal` physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.